Russell Investments Group Ltd. Has $24.88 Million Stake in Qiagen (NYSE:QGEN)

Russell Investments Group Ltd. reduced its holdings in Qiagen (NYSE:QGEN) by 11.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 571,813 shares of the company’s stock after selling 74,016 shares during the period. Russell Investments Group Ltd.’s holdings in Qiagen were worth $24,875,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Xponance Inc. raised its position in shares of Qiagen by 9.1% during the 3rd quarter. Xponance Inc. now owns 9,356 shares of the company’s stock valued at $379,000 after acquiring an additional 780 shares during the last quarter. Strs Ohio grew its stake in shares of Qiagen by 14.6% during the third quarter. Strs Ohio now owns 45,441 shares of the company’s stock worth $1,840,000 after purchasing an additional 5,774 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Qiagen by 16.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 255,837 shares of the company’s stock valued at $10,361,000 after purchasing an additional 35,297 shares during the last quarter. ING Groep NV lifted its stake in Qiagen by 28.4% in the third quarter. ING Groep NV now owns 257,392 shares of the company’s stock valued at $10,424,000 after buying an additional 56,901 shares during the period. Finally, First Trust Direct Indexing L.P. bought a new position in Qiagen during the third quarter worth about $253,000. 70.00% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

QGEN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, February 8th. Morgan Stanley upgraded shares of Qiagen from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $49.48 to $51.00 in a report on Friday, February 16th. Citigroup cut their target price on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a report on Thursday, February 8th. Finally, Stifel Nicolaus decreased their price target on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Qiagen currently has a consensus rating of “Moderate Buy” and an average target price of $50.95.

Qiagen Stock Up 1.1 %

Shares of QGEN stock opened at $42.81 on Thursday. Qiagen has a 12-month low of $34.74 and a 12-month high of $47.70. The company has a quick ratio of 1.62, a current ratio of 1.99 and a debt-to-equity ratio of 0.24. The firm has a fifty day moving average of $42.56 and a 200-day moving average of $42.71. The company has a market capitalization of $9.77 billion, a price-to-earnings ratio of 28.71, a P/E/G ratio of 3.58 and a beta of 0.42.

Qiagen (NYSE:QGEN) last announced its earnings results on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.50%. The firm had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same period in the prior year, the business earned $0.53 EPS. The company’s revenue for the quarter was down 5.4% compared to the same quarter last year. As a group, equities research analysts predict that Qiagen will post 2.09 earnings per share for the current fiscal year.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.